It’s not every day in pharma that a new class of drugs enters the pantheon of the best-selling medications of all time. But the emergence of Eli Lilly’s Zepbound and Mounjaro and Novo Nordisk’s Ozempic and Wegovy took the pharma world by storm. The diabetes and obesity medications have helped millions of patients address unmet needs and created wild market demand.
In keeping with the times, the PharmaVoice 100 introduced a new category this year to recognize the significant impact of this market. Meet the Cardiometabolic All-Stars, representing the standouts in the sector making big waves.
Some are advancing new therapies to work alongside diabetes and weight loss leaders, while others are forging new therapy paths to improve upon what’s already out there. These leaders include Big Pharma players making an impact by turning GLP-1s into household names, and those pushing the boundaries with novel approvals.
Here are this year’s Cardiometabolic All-Stars.
Robert Blum
“Biopharma has a way of humbling even the best and brightest leader amongst us.” Read more ➔
Kristen Fortney
“Aging biology will yield a wealth of novel targets that can improve health span on a broad scale.” Read more ➔
Vipin Garg
“It is exciting to see more emphasis being placed on [R&D] … to improve the quality and longevity of life.” Read more ➔
Negelle Morris
“Great leaders recognize the significance of fostering genuine connections within organizations.” Read more ➔
Rohan Palekar
“We are in an era of remarkable medical innovation, with discovery of new therapies and applications of new modalities to extend lives.” Read more ➔
Dr. Rebecca Taub
“The ability to endure and adapt while maintaining a clear [scientific] vision is what brings innovative treatments to patients.” Read more ➔
